Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 11, 481-484, July 1, 1951]
© 1951 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loefer, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loefer, J. B.

Effect of Pyridoxine and Desoxypyridoxine on Rat Fibrosarcoma Grafts*

John B. Loefer

( Foundation of Applied Research, San Antonio, Texas)

The incidence of fibrosarcomas, following subcutaneous grafting into 7-week-old control rats living on a Purina Laboratory Chow diet, was compared to that in rats which received supplements of pyridoxine and in others that were given desoxypyridoxine; 243 animals were used.

Pyridoxine supplements per rat totaled as much as 1,500 µg. over a 2-week period before implantation and up to 400 µg. following grafting. Desoxypyridoxine injections totaled as much as 110 mg. per rat preceding tumor injections and up to 40 mg. subsequently.

Tumor takes after 13–20 days in pyridoxinetreated rats averaged 40 per cent, as compared to takes of 16 and 11 per cent, respectively, in controls and desoxypyridoxine-treated animals. Pyridoxine deficiency symptoms were noted in only a few rats bearing tumors in the desoxypyridoxine-treated group.

Although this analog was also administered in relatively large amounts to nontumor-bearing hamsters on an identical basic diet over a period of 59 days, no vitamin B6 deficiency symptoms were observed.

* Supported in part by grants-in-aid from Mr. and Mrs. Lewis J. Moorman, Jr., and the American Cancer Society (#CBC5).

Received 8/ 7/50.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1951 by the American Association for Cancer Research.